Anixa Biosciences Announces Invited Presentation On Ovarian Cancer CAR-T Therapy At The 8th Annual CAR-TCR Summit
Portfolio Pulse from Happy Mohamed
Anixa Biosciences (NASDAQ:ANIX) announced that its Chief Development Officer, Dr. Pamela D. Garzone, will present at the 8th Annual CAR-TCR Summit. The presentation will focus on the development of CAR-T for ovarian cancer and other solid tumors, and will detail the ongoing clinical trial (NCT05316129) in collaboration with Moffitt Cancer Center. The trial is a Phase I clinical trial of autologous T cells genetically engineered to target the follicle-stimulating hormone receptor (FSHR) in patients with recurrent ovarian cancer.
August 14, 2023 | 12:58 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Anixa Biosciences' presentation at the CAR-TCR Summit could potentially increase investor interest in the company due to its ongoing clinical trial for ovarian cancer CAR-T therapy.
The presentation at a major industry event like the CAR-TCR Summit could increase visibility for Anixa Biosciences and its ongoing clinical trial. This could potentially attract more investors, leading to a positive impact on the company's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100